Odile Launay, MD, PhD

Head of I Reivac, French vaccine research network
Université Paris Cité; Inserm F-CRIN, I-REIVAC; Assistance Publique Hôpitaux de Paris, France

Disclosure(s): AstraZeneca: Financial; GlaxoSmithKline: Advisor/Consultant, Grant/Research Support; Johnson & Johnson: Advisor/Consultant, Grant/Research Support; MD: Advisor/Consultant; Moderna: Advisor/Consultant; MSD: Data safety monitoring board; Pfizer: Advisor/Consultant, Grant/Research Support; Sanofi Pasteur: Advisor/Consultant, Data safety monitoring board, Grant/Research Support

Poster(s):

• 1954 - Immunogenicity against SARS CoV-2 ancestral strain and variants of two new COVID-19 recombinant adjuvanted vaccines compared to BNT162b2 as a third dose following two doses of BNT162b2: a single-blinded multicenter randomized controlled trial
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET